Table 1.
Demographics and baseline biomarkers for first 90 subjects in Longitudinal Investigation for Enhancing Down Syndrome Research (LIFE-DSR) Study.
| Characteristic | Mean (SD) | Median (Q1, Q3) | Min, Max | N (%) |
|---|---|---|---|---|
| p-tau 217 pg/mL | 0.26 (0.38) | 0.14 (0.08, 0.25) | 0.01, 2.72 | 90 (100.00%) |
| p-tau 181 pg/mL | 1.22 (1.10) | 0.81 (0.59, 1.45) | 0.37, 7.40 | 90 (100.00%) |
| NfL pg/mL | 13.84 (7.19) | 11.90 (9.28, 18.06) | 5.13, 46.87 | 90 (100.00%) |
| GFAP pg/mL | 100.37 (57.02) | 84.74 (63.44, 123.65) | 36.19, 445.03 | 90 (100.00%) |
| Aβ1-40 pg/mL | 210.03 (52.36) | 215.82 (188.07, 234.87) | 66.32, 417.74 | 90 (100.00%) |
| Aβ1-42 pg/mL | 8.81 (2.42) | 8.90 (7.36, 10.24) | 2.22, 13.82 | 90 (100.00%) |
| Aβ42/Aβ40 ratio | 0.04 (0.01) | 0.04 (0.04, 0.05) | 0.01, 0.06 | 90 (100.00%) |
| DS-MSE Total Score 2 | 64.23 (11.25) | 65.00 (59.00, 72.00) | 30.00, 82.00 | 79 (87.78%) |
| SIB Total Score | 87.92 (14.04) | 93.00 (86.00, 96.50) | 14.00, 100.00 | 84 (93.33%) |
| Age (years) | 38.31 (9.47) | 37.00 (30.00, 45.00) | 25.00, 69.00 | 86 (95.56%) |
| Female | Male | |||
| Gender | 40 (46.51%) | 46 (53.49%) | ||
| Non-Carrier | Carrier | |||
| APOE ε4 | 67 (74.44%) | 23 (25.56%) |
Aβ1-40 = amyloid β peptide 1-40, Aβ1-42 = amyloid β peptide 1-42, APOE ε4 = apolipoprotein E ε4 allele, DS-MSE = Down Syndrome Mental Status Examination, GFAP = glial fibrillary acidic protein, Min = minimum, Max = maximum, N = number, NfL = neurofilament light, pg/mL = picogram/milliliter, p-tau 181 = phosphorylated tau at threonine-181, p-tau 217 = phosphorylated tau at threonine−217, Q1 = quartile 1, Q3 = quartile 3, SD = standard deviation, SIB = Severe Impairment Battery.